237 related articles for article (PubMed ID: 15347061)
1. [A compensated type 2 diabetic patient? Fasting blood glucose can be deceptive].
MMW Fortschr Med; 2004 Feb; 146(7):62. PubMed ID: 15347061
[No Abstract] [Full Text] [Related]
2. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Gribble FM; Manley SE; Levy JC
Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
[TBL] [Abstract][Full Text] [Related]
3. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
4. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
Abrahamian H; Francesconi M; Loiskandl A; Dzien A; Prager R; Weitgasser R
Diabetes Technol Ther; 2004 Feb; 6(1):31-7. PubMed ID: 15000767
[TBL] [Abstract][Full Text] [Related]
5. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
[TBL] [Abstract][Full Text] [Related]
7. [Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
MMW Fortschr Med; 2003 Aug; 145(33-34):59. PubMed ID: 14526583
[No Abstract] [Full Text] [Related]
8. Restoring post-prandial insulin release in type 2 diabetes.
Andrews J
Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
[TBL] [Abstract][Full Text] [Related]
9. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.
Li L; Yang M; Li Z; Yan X; Guo H; Pan H; Liu H; Liao Y; Yang G
Diabetes Obes Metab; 2012 Feb; 14(2):187-9. PubMed ID: 21895920
[TBL] [Abstract][Full Text] [Related]
11. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
Hazama Y; Matsuhisa M; Ohtoshi K; Gorogawa S; Kato K; Kawamori D; Yoshiuchi K; Nakamura Y; Shiraiwa T; Kaneto H; Yamasaki Y; Hori M
Diabetes Res Clin Pract; 2006 Mar; 71(3):251-5. PubMed ID: 16214255
[TBL] [Abstract][Full Text] [Related]
13. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
Salas M; Ward A; Caro J
Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
[TBL] [Abstract][Full Text] [Related]
14. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Ristic S; Collober-Maugeais C; Pecher E; Cressier F
Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
[TBL] [Abstract][Full Text] [Related]
15. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Israel MK; Istvan E; Baron MA
Vasc Health Risk Manag; 2008; 4(6):1167-78. PubMed ID: 19337530
[TBL] [Abstract][Full Text] [Related]
18. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
[TBL] [Abstract][Full Text] [Related]
19. Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Baron MA
Diabetes Care; 2003 Dec; 26(12):3361-2; author reply 3362-3. PubMed ID: 14633839
[No Abstract] [Full Text] [Related]
20. Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes.
Ai M; Tanaka A; Ogita K; Shimokado K
Diabetes Care; 2006 May; 29(5):1180. PubMed ID: 16644666
[No Abstract] [Full Text] [Related]
[Next] [New Search]